Building upon this foundation, the current study aims to investigate the clinical efficacy of serum ESPL1 in comparison to AFP and PIVKA-II for the early detection of HBV-HCC, and determine whether serum ESPL1 levels can be utilized as a novel and specific biomarker for the prompt diagnosis and screening of HBV-HCC. Here, AFP is linked to hepatocellular carcinoma.